Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fecal Molecular Susceptibility-guided Therapy for First-line H. Pylori Treatment
NCT07405684Phase 4Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 4 trial of tegoprazan, amoxicillin, clarithromycin, levofloxacin, bismuth subcitrate in Helicobacter pylori infection, sponsored by Zhongshan Hospital, Fudan University. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
tegoprazanamoxicillinclarithromycinlevofloxacinbismuth subcitrate
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT07405684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07405684.